HNGE Form 144/A: Insight Venture resale notices

Hinge Health, Inc. submitted a Form 144/A disclosure listing proposed resales of Class A shares by Insight Venture Partners X, L.P.

Rhea-AI Filing Summary

Hinge Health, Inc. submitted a Form 144/A disclosure listing proposed resales of Class A shares by Insight Venture Partners X, L.P. The excerpt shows multiple sale dates in June 2026 with per‑trade share counts and gross proceeds reported.

The filing also notes a Series B preferred stock conversion before IPO dated 07/03/2018 and a separate figure of 4,485,644 tied to securities wired to a portfolio company on that date.

Insights

Securities Counsel

Routine resale notices by a private equity holder over several June 2026 dates.

The excerpt lists multiple Class A share disposals by Insight Venture Partners X, L.P. with transaction dates ranging from 06/16/2026 to 06/29/2026 and explicit per‑trade share counts and gross proceeds reported in dollars.

Timing and method details beyond the per‑trade disclosures are not present in the excerpt; subsequent filings would show whether these were under an exemption or pursuant to an effective registration.

Key Figures

Trade date range: June 16–29, 2026 Largest per‑trade shares: 732,444 shares Largest per‑trade proceeds: $60,670,973.32 +2 more

5 metrics

Trade date range June 16–29, 2026 Dates of per‑trade disclosures by Insight Venture Partners X, L.P.

Largest per‑trade shares 732,444 shares Trade on <date>06/29/2026</date> reported in the excerpt

Largest per‑trade proceeds $60,670,973.32 Gross proceeds reported for the 732,444‑share line on <date>06/29/2026</date>

Other notable trades (examples) 265,169 shares; 266,290 shares Trades on <date>06/25/2026</date> and <date>06/24/2026</date> with proceeds listed

Historical conversion note 4,485,644 (units) Series B preferred conversion before IPO dated <date>07/03/2018</date>

Key Terms

Form 144/A, Series B preferred, resale notice

3 terms

Form 144/A regulatory

"144/A: Securities Sold During The Past 3 Months"

Series B preferred financial

"Series B Preferred | 07/03/2018 | Stock Conversion before IPO"

Series B preferred is a class of ownership created during a later private funding round that gives investors special rights ahead of ordinary shareholders. Think of it like a priority ticket at a crowded exit: holders get paid or reimbursed before common shareholders if the company is sold or winds down, often receive fixed payments or protection against value loss, and typically have options to convert into regular shares; those features affect potential returns and control for investors.

resale notice regulatory

"144/A: Securities To Be Sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does HNGE's Form 144/A show about Insight Venture Partners' activity?

It lists multiple proposed resales by Insight Venture Partners X, L.P., including trade dates from 06/16/2026 through 06/29/2026 and per‑trade share counts such as 732,444 on 06/29/2026 with reported gross proceeds.

How many shares and proceeds are shown for the largest June 2026 trade?

The excerpt shows a 732,444 shares trade on 06/29/2026 with reported gross proceeds of $60,670,973.32, as presented in the filing's per‑trade line item for that date.

Does the filing register new securities or describe an offering for Hinge Health?

The document is a Form 144/A resale notice listing proposed sales by a holder; it does not on its face register new securities or state offering terms such as aggregate registered amount or use of proceeds.

What historical conversion is mentioned in the excerpt?

The excerpt references a Series B preferred stock conversion before IPO dated 07/03/2018 and notes 4,485,644 tied to securities wired to a portfolio company on that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 05:48 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK	0001710959
Filer CCC	XXXXXXXX
Previous Accession Number Of The Filing	0001974078-26-000263
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer	Hinge Health, Inc.
SEC File Number	001-42657
Address of Issuer	455 MARKET STREET 7TH FLOOR SAN FRANCISCO CALIFORNIA 94105
Phone	415-689-8429
Name of Person for Whose Account the Securities are To Be Sold	Insight Venture Partners X, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	10% Stockholder

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Raymond James & Associates 880 Carillon Parkway St. Petersburg FL 33716	732444	65919960.00	54655926	07/07/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Series B Preferred	07/03/2018	Stock Conversion before IPO	Hinge Health, Inc.			4485644	07/03/2018	Wired to portfolio company

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Insight Venture Partners X, L.P. 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	06/16/2026	32751	2304347.26
Insight Venture Partners X, L.P. 1114 Avenue of the Americas, 36th Floor New York NY 10036	Class A	06/22/2026	112064	7951400.26
Insight Venture Partners X, L.P. 1114 Avenue of the Americas, 36th Floor New York NY 10036	Class A	06/23/2026	56171	3944018.68
Insight Venture Partners X, L.P 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	06/24/2026	266290	18963363.03
Insight Venture Partners X, L.P 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	06/25/2026	265169	19045365.67
Insight Venture Partners X, L.P 114 Avenue of the Americas 36th Floor New York NY 10036	Class A	06/29/2026	732444	60670973.32

144/A: Remarks and Signature

Remarks
Date of Notice	07/07/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/20/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Insight Venture Partners X ,L P
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)